Cipla stock
Price history
−7.47% over the period1 year: from ₹1,529.20 (November 20, 2025) to ₹1,415.00 (November 20, 2026), −7.47%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | ₹1,415.00 |
| October 30, 2026 | ₹1,378.90 |
| September 30, 2026 | ₹1,346.00 |
| August 31, 2026 | ₹1,409.20 |
| July 31, 2026 | ₹1,473.20 |
| June 30, 2026 | ₹1,465.40 |
| May 29, 2026 | ₹1,401.00 |
| April 30, 2026 | ₹1,309.60 |
| March 30, 2026 | ₹1,224.20 |
| February 27, 2026 | ₹1,348.20 |
| January 30, 2026 | ₹1,324.00 |
| December 31, 2025 | ₹1,511.30 |
| November 28, 2025 | ₹1,531.30 |
| November 20, 2025 | ₹1,529.20 |
At a glance
The company
Manufactures and distributes generic and branded pharmaceutical products, vaccines, and active ingredients across multiple therapeutic areas globally
Latest results
Quarter to September 30, 2026 · EPS ₹10.85 (estimate ₹11.54)
Next event
TickerLandia's take on Cipla
- Priced as usual relative to earnings: P/E on the latest fiscal year 29 vs a median of 28 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 39 vs 29 (+38%) in a group of 11.
- Strong point: Financial strength (81/100 in its group). Weak point: Profitability (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.10% from the 52-week high
Analysts · 36 analysts
Average target₹1,507.31+6.52% vs. price
Buy 22 · Hold 12 · Sell 2 · Buy
TickerLandia Fingerprint: Cipla
Compared with similar companies: very low risk and very high financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh64
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 39.5 73 Forward P/E 24.9 63 Price/book 3.24 53 EV/EBITDA 22.3 68 Price/sales 4.10 64 Profitabilitylow33
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 13.0% 27 ROA 5.5% 37 ROE 8.3% 27 Gross margin 62.7% 40 Net margin 10.4% 35 Earnings stabilityhigh65
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.6% 67 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Financial strengthvery high81
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.02 91 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.09 72 Interest coverage 100.4 78 Current ratio 3.59 83 Dividendaverage58
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 36.3% 50 Dividend yield 0.9% 31 Consecutive dividend years 30 years 92 Market momentumaverage54
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −7.47% 37 Distance from 200-day average +3.50% 72 Riskvery low11
How much the price swings.
Metric Value Position in group Volatility (60 days) 14.6% 1 Maximum drawdown (12 months) 22.1% 20
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Cipla is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2026), Cipla's P/E today is 29.5, in line with the median of its last 10 fiscal years (27.6; between 22.1 and 47.4 from 2017 to 2026). Cipla's P/E (trailing 12 months): 39.5, +38% against the median of a group of 11 similar companies (28.7).
Compared with 11 similar companies
| Metric | Cipla | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 39.5 | Middle | |
| Forward P/E | 22.7 | Middle | |
| Operating margin | 13.0% | Low | |
| ROE | 8.3% | Low | |
| Debt/equity | 0.02 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Cipla. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₹73.68B
Latest quarter · Q3 2026
Net income
₹8.78B
Latest quarter · Q3 2026
Quarterly net margin
11.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ₹1.14T
- P/E
- 39.5
- EPS
- ₹35.84
- Volume
- 1.48M
- Daily trading
- €21.37M
- Dividend yield
- 0.92%
- Last ex-dividend on June 5, 2026
How Cipla is changing
All resultsRevenue grew 7.8% a year on average over the last 5 years
Free cash flow equal to 69% of net income
Revenue has grown for 9 fiscal years in a row
Returns
Cipla returns with dividends
₹1,000 invested in Cipla 5 years ago, on November 22, 2021, would be worth ₹1,647 today with dividends reinvested: +64.68% in total, +10.50% per year. On price alone it would be ₹1,580 (+58.03%).
| Period | Cipla | ₹1,000 becomes |
|---|---|---|
| 1 month | +7.69% | ₹1,077 |
| 6 months | +1.11% | ₹1,011 |
| Year to date | −6.37% | ₹936 |
| 1 year | −6.61% | ₹934 |
| 3 years | +16.72% | ₹1,167 |
| 5 years | +64.68% | ₹1,647 |
| 10 years | +178.75% | ₹2,788 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Cipla: technical analysis
Cipla shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 15.8% below its all-time closing high (₹1,680.50, October 9, 2024).
- Trend
- No clear trend
- RSI (14 sessions)
- 61
- Between 30 and 70
- vs 200-session average
- +3.50%
Active signals
Death cross: the 50-session average has crossed below the 200-session average.
since November 12, 2026
Support and resistance
Price areas where Cipla has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance₹1,532.83+8.33%3 touches, last on January 6, 2026
- Resistance₹1,482.67+4.78%7 touches, last on August 6, 2026
- Resistance₹1,424.80+0.69%3 touches, last on November 9, 2026
- Last price₹1,415.00
- Support₹1,365.50−3.50%2 touches, last on July 23, 2026
- Support₹1,347.82−4.75%5 touches, last on September 16, 2026
- Support₹1,312.30−7.26%2 touches, last on February 23, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 14.6%
- Largest fall in the last year
- −22.13%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Cipla: seasonality
Average monthly price change over 31 years
Over the last 31 years, the strongest month for Cipla has been July: +4.51% on average, positive in 22 years out of 31. The weakest has been January: −1.53% on average, positive in 11 years out of 30. November, the current month, has been positive in 14 years out of 30 (+1.87% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.53% | −2.12% | 11 of 30 |
| February | −1.31% | −2.11% | 10 of 31 |
| March | +3.32% | +2.09% | 19 of 31 |
| April | +3.08% | +3.24% | 20 of 31 |
| May | −1.21% | −1.09% | 13 of 31 |
| June | +2.63% | +2.74% | 21 of 31 |
| July | +4.51% | +4.22% | 22 of 31 |
| August | +4.02% | +3.02% | 21 of 31 |
| September | +3.29% | +2.11% | 19 of 31 |
| October | +0.93% | −0.19% | 14 of 31 |
| November | +1.87% | −0.28% | 14 of 30 |
| December | +2.19% | +1.55% | 18 of 30 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Cipla and its competitors
Customers in India, the United States and South Africa, along with buyers in other countries, are the markets this Mumbai-based drugmaker serves. Its products include off-patent medicines sold as generics and under its own brand names, alongside vaccines and the active ingredients used to make finished drugs. The range covers treatments for respiratory conditions, HIV/AIDS, heart and kidney disease, diabetes, oncology, child health and critical care, and the company also runs consumer healthcare, biosimilars and specialty businesses.
- Headquarters
- Mumbai, India
- Employees
- 31,369
- Founded
- 1935
- Chief executive
- Achin Gupta
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| CiplaCIPLA | $12.34B | 13.0% | 39.5 | +1.11% |
| Zhejiang NHU002001 | $11.61B | 33.8% | 10.6 | −19.16% |
| Zydus LifesciencesZYDUSLIFE | $12.92B | 17.2% | 28.7 | +15.29% |
| Laurus LabsLAURUSLABS | $14.13B | 24.1% | 97.8 | +68.58% |
| Yunnan Baiyao Group000538 | $15.07B | 11.2% | 19.4 | +11.07% |
| PharmaEssentia6446 | $15.94B | 38.4% | 74.1 | +54.65% |
Same industry or related industries, similar size. Compare Cipla with its competitors · Full profile
